Kozloff, Mark

Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer

Catenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology

Pancreatic and Hepatic Oncology ResearchHedgehog Signaling Pathway Studies

Cited by 561

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Melisi, D., Garcia-Carbonero, R., Macarulla, T., Pezet, D., Deplanque, G., Fuchs, M., Trojan, J., Oettle, H., Kozloff, M., Cleverly, A., et al. (2018) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 294